CancerPPD

This page gives details of Query peptides and provides facility to browse the same in CancerPPD database. Please wait while data is being retrieved. For more information see HELP page.

ID	PMID	SEQUENCE	NAME	LENGTH	ACTIVITY
1033	14499271	FLPLLAGLAANFLPTIICKISYKC	GGN6	24	IC₅₀=4.88 µg/ml
1034	14499271	LLAGLAANFLPTIICKISYKC	PTP1	21	IC₅₀=>100 µg/ml
1035	14499271	FAGLAANFLPTIICKISYKC	PTP2	20	IC₅₀=>100 µg/ml
1036	14499271	FLKLLKKLAAKFLPTIICKISYKC	PTP4	24	IC₅₀=18.1 µg/ml
1037	14499271	FLKLLKKLAAKLF	PTP5	13	IC₅₀=5.43 µg/ml
1038	14499271	FLKLLKKLAAKLF	PTP6	13	IC₅₀=17.56 µg/ml
1039	14499271	FLGALFKALSKLL	PTP7	13	IC₅₀=5.25 µg/ml
1040	14499271	FLKLLAGLLKNFA	PTP8	13	IC₅₀=32.23 µg/ml
1059	18617323	RAGLQFPVGRLLRRLLRRLLR	Buforin IIb	21	IC₅₀=15.1 µg/ml
1248	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=42.5 µM
1251	7849420	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL	Cecropin B	35	IC₅₀=24.5
1402	1708887, 2285300	GIGKFLHAAKKFAKAFVAEIMNS	Magainin B	23	IC₅₀=37 µg/ml
1403	1708887, 2285300	GIGKFLHSAKKFAKAFVAEIMNS	Magainin G	23	IC₅₀=42 µg/ml
1404	1708887, 2285300	AIGKFLHSAKKFGKAFVGEIMNS	Magainin A	23	IC₅₀=49 µg/ml
1405	1708887, 2285300	ALSKALSKALSKALSKALSKALSK	Z44	24	Not Available
1406	1708887, 2285300	ALSKALSKALSKALSKALSKALSK	Z24	24	Not Available
1407	1708887, 2285300	GIGKFLHSAKKFGKAFVGEIMNS	Magainin 2	23	IC₅₀ >200 µg/ml
1465	21252288	KWKSFAKTFKSAKKTVAHTALKAISS	L6A/L17A	26	IC₅₀=>83.6 µMo/L
1466	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L17A/L21A	26	IC₅₀=>83.6 µMo/L
1467	21252288	KWKSFLKTFKSAKKTVAHTALKAISS	L17A	26	IC₅₀=>83.6 µMo/L
1468	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L21A	26	IC₅₀=70.8 µMo/L
1469	21252288	KWKSFAKTFKSAKKTVLHTALKAISS	L6A	26	IC₅₀=62.3 µMo/L
1470	21252288	KWKSFLKTFKSAKKTVLHTALKAISS	P	26	IC₅₀=15.8 µMo/L
1471	21252288	KWKSFLKTFKSLKKTVLHTALKAISS	A12L	26	IC₅₀=5 µMo/L
1472	21252288	KWKSFLKTFKSAKKTVLHTLLKAISS	A20L	26	IC₅₀=5.1 µMo/L
1473	21252288	KWKSFLKTFKSLKKTVLHTLLKAISS	A12L/A20L	26	IC₅₀=6.2 µMo/L
1474	21252288	KWKSFLKTFKSLKKTVLHTLLKLISS	A12L/A20L/A23L	26	IC₅₀=5.7 µMo/L
1706	9614066	ALWKNMLKGIGKLAGQAALGAVKTLVGA	DRS B3	28	Cytotoxicity =12 µM
1707	9614066	ALWKDILKNVGKAAGKAVLNTVTDMVNQ	DRS B4	28	Cytotoxicity =15 µM
1708	9614066	ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ	DRS S1	35	Not Available
1773	None	FALALKALKKALKKLKKALKKAL	Hecate Ac	23	LD₅₀ =54 µg/ml
1774	None	FALALKALKKALKKLKKALKKAL	Hecate AM	23	LD₅₀ =23 µg/ml
1775	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AC	38	LD₅₀ =175 µg/ml
1776	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AM	38	LD₅₀ =540 µg/ml
1777	None	FAKKLAKKLKKLAKKLAKLALAL	SHIVA 10 AC	23	LD₅₀ =>1000 µg/ml
1778	None	FALAAKALKKLAKKLKKLAKKAL	FLAK01 AM	23	LD₅₀ =62 µg/ml
1779	None	FALALKALKKLLKKLKKLAKKAL	FLAK03 AM	23	LD₅₀ =26 µg/ml
1780	None	FALALKALKKLAKKLKKLAKKAL	FLAK04 AM	23	LD₅₀ =10 µg/ml
1781	None	FALAKLAKKAKAKLKKALKAL	FLAK05 AM	21	LD₅₀ =74 µg/ml
1782	None	FALALKALKKLKKALKKAL	FLAK06 AM	19	LD₅₀ =14 µg/ml
1783	None	FALALKALKKLKKALKKAL	FLAK06 AC	19	LD₅₀ =65 µg/ml
1784	None	FAKKLAKKLKKLAKLALAL	FLAK06 R-AC	19	LD₅₀ =140 µg/ml
1785	None	VALALKALKKALKKLKKALKKAL	KAL V	23	LD₅₀ =72 µg/ml
1786	None	FALALKKALKALKKAL	FLAK 17 AM	16	LD₅₀ =21 µg/ml
1787	None	FAKKLAKLAKKLAKLAL	FLAK 26 AM	17	LD₅₀ =9 µg/ml
1788	None	FAKKLAKLAKKLAKLALAL	FLAK 25 AM	19	LD₅₀ =9 µg/ml
1789	None	FALALKALKKALkkLKKALKKAL	HECATE 2DAc	23	LD₅₀ =14 µg/ml
1790	None	FAKKLAKLAKKLLAL	FLAK43 AM	15	LD₅₀ =17 µg/ml
1791	None	FAKKLAKLAKKALAL	FLAK44 AM	15	LD₅₀ =130 µg/ml
1792	None	FALAKKALKKAKKAL	FLAK62 AM	15	LD₅₀ =760 µg/ml
1793	None	FAKKLAKKLKKLAKLALAK	FLAK 06R-AM	19	LD₅₀ =98 µg/ml
1794	None	GIGKFLKKAKKFGKAFVKILKK	MSI-78 AM	22	LD₅₀ =31 µg/ml
1795	None	FAKLLAKLAKKLL	FLAK50	13	LD₅₀ =9 µg/ml
1796	None	FAKKLAKLALKLAKL	FLAK51	15	LD₅₀ =140 µg/ml
1797	None	FAKKLAKKLAKLAL	FLAK57	14	LD₅₀ =260 µg/ml
1798	None	FAKKLKKLAKLAKKL	FLAK71	15	LD₅₀ =300 µg/ml
1799	None	FAKKALKALKKL	FLAK77	12	LD₅₀ =575 µg/ml
1800	None	VAKLLAKLAKKLL	FLAK50V	13	LD₅₀ =23 µg/ml
1801	None	FAKLLAKLAKKL	FLAK50F	12	LD₅₀ =40 µg/ml
1802	None	VAKKLAKLAKKLAKLAL	FLAK26V AM	17	LD₅₀ =32 µg/ml
1803	None	KWKLFKKIGAVLKVL	CAME-15	15	LD₅₀ =45 µg/ml
1804	None	FAKLLAKLAKKAL	FLAK50C	13	LD₅₀ =60 µg/ml
1805	None	FAKLLAKALKKLL	FLAK50D	13	LD₅₀ =16 µg/ml
1806	None	FAKLLKLAAKKLL	FLAK 50E	13	LD₅₀ =500 µg/ml
1807	None	FAKLLAKKLL	FLAK80	10	LD₅₀ =>1000 µg/ml
1808	None	FAKKLAKALL	FLAK81	10	LD₅₀ =>1000 µg/ml
1809	None	FAKKLAKKLL	FLAK82	10	LD₅₀ =31 µg/ml
1810	None	FAKLAKKLL	FLAK83M	9	LD₅₀ =>1000 µg/ml
1811	None	FAKKLAKLAKKLAKLAL	FLAK 26 Ac	17	LD₅₀ =105 µg/ml
1812	None	ILPWKWPWWPWRR	Indolicidin	13	LD₅₀ =64 µg/ml
1813	None	FAKALKALLKALKAL	FLAK 17 C	15	LD₅₀ =80 µg/ml
1814	None	FAKLLAKLAKAKL	FLAK 50H	13	LD₅₀ =475 µg/ml
1815	None	FAKLLAKLAKLKL	FLAK 50G	13	LD₅₀ =90 µg/ml
1816	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA DERIV P69 + KWKL	22	LD₅₀ =44 µg/ml
1817	None	FAKKLAKKLKKLAKKLAK	Shiva 10(1-18 AC)	18	LD₅₀ =190 µg/ml
1818	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA 10 PEPTIDE 71 + KWKL	22	LD₅₀ =93 µg/ml
1819	None	KWKLFKKKTKLFKKFAKKLAKKL	CA (1-7) Shiva10 (1-16)	23	LD₅₀ =150 µg/ml
1820	None	FAKKLAKKLAKAL	FLAK 54	13	LD₅₀ =465 µg/ml
1821	None	FAKKLAKKLAKLL	FLAK 56	13	LD₅₀ =42 µg/ml
1822	None	FAKKLAKKLAKAAL	FLAK 58	14	LD₅₀ =970 µg/ml
1823	None	FAKKLAKKAKLAKKL	FLAK 72	15	LD₅₀ =>1000 µg/ml
1824	None	FAKKLKKLAKKL	FLAK 75	12	LD₅₀ =540 µg/ml
1825	None	KTKLFKKFAKKLAKKLKKLAKKL	SHIVA 10 (1-16) Ac	23	LD₅₀ =29 µg/ml
1826	None	KWKLFKKKTKLFKKFAKKLAKKL	CA(1-7) Shiva10(1-16)-COOH	23	LD₅₀ =63 µg/ml
1827	None	ILPWKWPWWPWRR	Indolocidin-ac	13	LD₅₀ =12 µg/ml
1828	None	FAKALAKLAKKLL	FLAK50B	13	LD₅₀ =23 µg/ml
1829	None	FAKLLALALKLKL	FLAK50I	13	LD₅₀ =65 µg/ml
1830	None	FAKLLAKLAKAKA	FLAK50K	13	LD₅₀ =>1000 µg/ml
1831	None	FAKLLAKLAKAKG	FLAK50L	13	LD₅₀ =>1000 µg/ml
1832	None	FAKKLAKKLKKLAKKLAKLALALKALALKAL	Shiva-11	31	LD₅₀ =96 µg/ml
1833	None	FAKKLAKKLKKLAKKLIGAVLKV	SHIVA 11[(1-16)ME(2-9]-COOH	23	LD₅₀ =95 µg/ml
1834	None	FAKLLAKALKLKL	FLAK 50N	13	LD₅₀ =250 µg/ml
1835	None	FAKLLAKALKKAL	FLAK 50O	13	LD₅₀ =60 µg/ml
1836	None	FAKLLAKALKKL	FLAK 50P	12	LD₅₀ =46 µg/ml
1837	None	KWKLFKKALKKLKKALKKAL	CA(1-& HECATE(11/23)	20	LD₅₀ =11 µg/ml
1838	None	KIAKVALAKLGIGAVLKVLTTGL	PYL-ME	23	LD₅₀ =635 µg/ml
1839	None	FAKKLAKLAKKL	FLAG26-D1	12	LD₅₀ =620 µg/ml
1840	None	MPKEKVFLKIEKMGRNIRN	VISHNU3	19	LD₅₀ =>1000 µg/ml
1841	None	GIGAVLKVLTTGLPALISWIKRKRQQ	MELITTIIN	26	LD₅₀ =9 µg/ml
1842	None	FAKKLAKLAKKLAKAL	FLAK26-D2	16	LD₅₀ =>1000 µg/ml
1843	None	FAKKLLAKALKL	FLAG26-D3	12	LD₅₀ =180 µg/ml
1844	None	FAKFLAKFLKKAL	FLAK50 Q1	13	LD₅₀ =35 µg/ml
1845	None	FAKLLFKALKKAL	FLAK50 Q2	13	LD₅₀ =500 µg/ml
1846	None	FAKLLAKFLKKAL	FLAK50 Q3	13	LD₅₀ =150 µg/ml
1847	None	FAKLLAKAFKKAL	FLAK50 Q4	13	LD₅₀ =730 µg/ml
1848	None	FAKLFAKAFKKAL	FLAK50 Q5	13	LD₅₀ =>1000 µg/ml
1849	None	FAKLLAKALKKFL	FLAK50 Q6	13	LD₅₀ =70 µg/ml
1850	None	FAKLLAKALKKFAL	FLAK50 Q7	14	LD₅₀ =54 µg/ml
1851	None	FAKLLAKLAKKFAL	FLAK50 Q8	14	LD₅₀ =730 µg/ml
1852	None	FAKLFAKLAKKFAL	FLAK50 Q9	14	LD₅₀ =400 µg/ml
1853	None	FKLAFKLAKKAFL	FLAK50 Q10	13	LD₅₀ =360 µg/ml
1854	None	FAKLLAKLAK	FLAK50 T1	10	LD₅₀ =615 µg/ml
1855	None	FAKLLAKLAKKVL	FLAK50 T2	13	LD₅₀ =18 µg/ml
1856	None	FAKLLAKLAKKIL	FLAK50 T3	13	LD₅₀ =90 µg/ml
1857	None	FAKLLAKLAKKEL	FLAK50 T4	13	LD₅₀ =>1000 µg/ml
1858	None	FAKLLAKLAKKSL	FLAK50 T5	13	LD₅₀ =440 µg/ml
1859	None	FAKLA	FLAK90	5	LD₅₀ =500 µg/ml
1860	None	FAKLF	FLAK91	5	LD₅₀ =>1000 µg/ml
1861	None	KAKLF	FLAK92	5	LD₅₀ =>1000 µg/ml
1862	None	KWKLF	FLAK93	5	LD₅₀ =600 µg/ml
1863	None	FGKGIGKVGKKLL	FLAK50 Z1	13	LD₅₀ =>1000 µg/ml
1864	None	FAFGKGIGKVGKKLL	FLAK50 Z2	15	LD₅₀ =>1000 µg/ml
1865	None	FAKAIAKIAFGKGIGKVGKKLL	FLAK50 Z3	22	LD₅₀ =>1000 µg/ml
1866	None	FAKLWAKLAFGKGIGKVGKKLL	FLAK50 Z4	22	LD₅₀ =54 µg/ml
1867	None	FAKLWAKLAKKL	FLAK50 Z5	12	LD₅₀ =500 µg/ml
1868	None	FAKGVGKVGKKAL	FLAK50 Z6	13	LD₅₀ =>1000 µg/ml
1869	None	FAFGKGIGKIGKKGL	FLAK50 Z7	15	LD₅₀ =>1000 µg/ml
1870	None	FAKIIAKIAKIAKKIL	FLAK50 Z8	16	LD₅₀ =625 µg/ml
1871	None	FAFAKIIAKIAKKII	FLAK50 Z9	15	LD₅₀ =>1000 µg/ml
1872	None	FALALKA	FLAK94	7	LD₅₀ =430 µg/ml
1873	None	KWKLAKKALALL	FLAK93B	12	LD₅₀ =44 µg/ml
1874	None	FAKIIAKIAKKI	FLAK50 Z10	12	LD₅₀ =>1000 µg/ml
1875	None	FALALKALKKAL	FLAK96	12	LD₅₀ =150 µg/ml
1876	None	FALKALKK	FLAK97	8	LD₅₀ =>1000 µg/ml
1877	None	KYKKALKKLAKLL	FLAK98	13	LD₅₀ =110 µg/ml
1878	None	FKRLAKIKVLRLAKIKR	FKRLA	17	LD₅₀ =106 µg/ml
1879	None	FAKLAKKALAKLL	FLAK91B	13	LD₅₀ =315 µg/ml
1880	None	KAKLAKKALAKLL	FLAK92B	13	LD₅₀ =>1000 µg/ml
1881	None	KLALKLALKALKAAKLA	FLAK99	17	LD₅₀ =160 µg/ml
1882	None	FAKLLAKLAKK	FLAK50T6	11	LD₅₀ =>1000 µg/ml
1883	None	FAKLLAKLAKKGL	FLAK50T7	13	LD₅₀ =430 µg/ml
1884	None	FALKALKKLKKALKKAL	FLAK95	17	LD₅₀ =64 µg/ml
1885	None	VAKLLAKLAKKVL	FLAK50T8	13	LD₅₀ =315 µg/ml
1886	None	YAKLLAKLAKKAL	FLAK50T9	13	LD₅₀ =>1000 µg/ml
1887	None	KLLKLLLKLYKKLLKLL	FLAK100-CO2H	17	LD₅₀ =135 µg/ml
1888	None	FAVGLRAIKRALKKLRRGVRKVAKDL	FAGVL	26	LD₅₀ =240 µg/ml
1889	None	KLAKKLAKLAKLAKAL	Modelin-5	16	LD₅₀ =61 µg/ml
1890	None	KLAKKLAKLAKLAKAL	Modelin-5-CO2H	16	LD₅₀ =320 µg/ml
1891	None	FALALKALKKL	FLAK120	9	LD₅₀ =360 µg/ml
1892	None	FALAKALKKAL	FLAK121	11	LD₅₀ =>1000 µg/ml
1893	None	FALALKLAKKAL	FLAK96B	12	LD₅₀ =230 µg/ml
1894	None	FALLKL	FLAK96G	6	LD₅₀ =630 µg/ml
1895	None	FALALKALKK	FLAK96F	10	LD₅₀ =510 µg/ml
1896	None	FALKALKKAL	FLAK96C	10	LD₅₀ =940 µg/ml
1897	None	FALLKALKKAL	FLAK96D	11	LD₅₀ =305 µg/ml
1898	None	KFKKLAKKF	Modelin-8D	9	LD₅₀ =>1000 µg/ml
1899	None	KFKKLAKKW	Modelin-8E	9	LD₅₀ =>1000 µg/ml
1900	None	FALALKALKKA	Flak 96H	11	LD₅₀ =>1000 µg/ml
1901	None	FALLKALLKKAL	Flak 96I	12	LD₅₀ =190 µg/ml
1902	None	FALALKLAKKL	Flak 96J	11	LD₅₀ =770 µg/ml
1903	None	LKKLAKLALAF	Flak 96L	11	LD₅₀ =555 µg/ml
1904	None	VALALKALKKL	FLAK-120G	11	LD₅₀ =950 µg/ml
1905	None	FALALKLKKL	FLAK-120D	10	LD₅₀ =550 µg/ml
1906	None	FALALKAKKL	FLAK-120C	10	LD₅₀ =>1000 µg/ml
1907	None	FALA	FLAK-120B	4	LD₅₀ =>1000 µg/ml
1908	None	WALAL	FLAK-120F	5	LD₅₀ =260 µg/ml
1909	None	GIGKFLHAAKKFAKAFVAEIMNS	Magainin2wisc	23	LD₅₀ =22 µg/ml
1910	None	FAKKFAKKFKKFAKKFAKFAFAF	D2A21	23	LD₅₀ =64 µg/ml
1911	None	KKVVFKVKFK	KSL-1	10	LD₅₀ =340 µg/ml
1912	None	FKVKFKVKVK	KSL-7	10	LD₅₀ =315 µg/ml
1913	None	LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	LSB-37	38	LD₅₀ =50 µg/ml
1914	None	FAKKLAKKLKKLAKKLAKLAKKL	Anubis-2	23	LD₅₀ =38 µg/ml
1915	None	FAKKLAKLAKKLAKLALAL	FLAK 17 CV	19	LD₅₀ =23 µg/ml
1916	None	VAKFLAKFLKKAL	FLAK50 Q1V	13	LD₅₀ =92 µg/ml
1917	None	VAKKFAKKFKKFAKKFAKFAFAF	D2A21V	23	LD₅₀ =210 µg/ml
1918	None	VAKKLAKLAKKLAKLALAL	FLAK 25 AM V	19	LD₅₀ =130 µg/ml
1919	None	VAKKLAKLAKKLLAL	FLAK43 AM V	15	LD₅₀ =86 µg/ml
1920	None	VAKLLAKALKKLL	FLAK50D V	13	LD₅₀ =45 µg/ml
1921	None	VALALKALKKALKKLKKALKKAL	Hecate AM V	23	LD₅₀ =340 µg/ml
1922	None	VALALKALKKALKKLKKALKKAL	Hecate AC V	23	LD₅₀ =160 µg/ml
1923	None	VALALKALKKLAKKLKKLAKKAL	FLAK04 AM V	23	LD₅₀ =84 µg/ml
1924	None	FAKLLAKLAKKAA	FLAK50J	13	Not Available
2853	23577112, 21871946	FVDLKKIANIINSIF	Tempoprin-1CEa	15	61% Cell viability at 40 µM
2854	23577112, 21871946	FVDLKKIANIINSIF	Tempoprin-1CEa	15	32% Cytotoxicity at 40 µM
3096	16004618	MRKEFHNVLSSGQLLADKRPARDYNRK	Pep27	27	IC₅₀= >70 µM
3097	16004618	MWKWFHNVLSSWQLLADKRPARDYNRK	Pep27anal1	27	IC₅₀= 55 µM
3098	16004618	MWKWFHNVLSWWWLLADKRPARDYNRK	Pep27anal2	27	IC₅₀= <10 µM
3099	16004618	MRKWFHNVLSSGQLLADKWPAWDYNRK	Pep27anal3	27	IC₅₀= 38 µM
3100	16004618	MWKEFHNVLSSGQLLADKRWARWYNRW	Pep27anal4	27	IC₅₀= 29 µM
3101	16004618	MWKWFHNVLSSGQLLADKWWAWWYNWW	Pep27anal5	27	IC₅₀=>70 µM
3114	23993331	KWLRRVWRWWR	MAP-04-03	11	Cell viability >80% at 25 µM
3115	23993331	KWLRRVWRWWR	MAP-04-03	11	Cell viability ~50% at 50 µM
3116	23993331	KWLRRVWRWWR	MAP-04-03	11	Cell viability <40% at 75 µM
3117	23993331	KWLRRVWRWWR	MAP-04-03	11	Cell viability >20% at 100 µM
3118	23993331	KWLRRVWRWWR	MAP-04-03	11	Cell viability ~100% at 25 µM
3119	23993331	KRLRRVWRRWR	MAP-04-04	11	Cell viability >80% at 50 µM
3120	23993331	KRLRRVWRRWR	MAP-04-04	11	Cell viability >80% at 75 µM
3121	23993331	KRLRRVWRRWR	MAP-04-04	11	Cell viability >80% at 100 µM
3122	23993331	KWLRRVWRWWR	MAP-04-03	11	IC₅₀=61.5 µM
3127	23770440	FLGMIPGLIGGLISAFK	TsAP-2	17	IC₅₀ = 6.4 µM
3132	23770440	FLSLIPKLVKKIIKAFK	TsAP-S1	17	IC₅₀ = 1.8 µM
3137	23770440	FLGMIPKLIKKLIKAFK	TsAP-S2	17	IC₅₀ = 1.8 µM
3191	17787026	(K-Aib-C(CH2CO-2'-Pac))4	Dimer of peptide-paclitaxel conjugate	3	IC₅₀ =0.62nM
3194	17787026	(K-Aib-C(CH2CO-2'-Pac))3	Trimer of peptide-paclitaxel conjugate	3	IC₅₀ =3.00nM
3197	17787026	(K-Aib-C(CH2CO-2'-Pac))4	Tetramer of peptide-paclitaxel conjugate	3	IC₅₀ =0.64nM
3216	22413859	KVKVKVKVpPTKVKVKVK	SVS-1	18	IC_{50_{=8.1±0.8 µM}}
3220	22413859	kvkvkvkvPptkvkvkvk	D-SVS-1	18	IC₅₀ =4.7±0.4 µM
3224	22413859	KVKVKVKVPPTKVKVKVK	SVS-2	18	IC₅₀ >100 µM
3816	22963485	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLAN NFVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRA FKQL	wtmda-7/IL-24	206	Cell viability(% of control)=0.5 at concentration 7 µg/ml
3818	22963485	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAF KQLDVEAALTKALGEVDILLTWMQKFYKL	RGD-mda-7	207	Cell viability(% of control)=0.5 at concentration 4 µg/ml
3820	22963485	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANN FVLIVSQLQPSQENEMFSIRDSAHRRFLLFRRAF KQL	wtmda-7/IL-24	206	Apoptotic rate(%)= >50% at concentration of 8 µg/ml
3823	22963485	MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG AQGQEFHFGPCQVKGVVPQKLWEAFWAVKDTMQAQDNITSARLLQQEVLQ NVSDAESCYLVHTLLEFYLKTVFKNYHNRTVEVRTLKSFSTLANNF VLIVSQLQPSQENEMFSIRGDSAHRRFLLFRRAFK QLDVEAALTKALGEVDILLTWMQKFYKL	RGD-mda-7	207	Apoptotic rate(%)= >70% at concentration of 8 µg/ml
3870	16722632	YA*	8	2	2.4% inhibition at 10^-5
3871	16722632	YA*	8	2	7.5% inhibition at 10^-4
3894	16722632	YSA*	9	3	1.1% inhibition at 10^-5
3895	16722632	YSA*	9	3	1.2% inhibition at 10^-4
3896	16722632	YSA*	9	3	17.8% inhibition at 10^-3
3915	16722632	YSA*	10	3	7.7% inhibition at 10^-4M
3916	16722632	YSA*	10	3	18.7% inhibition at 10^-3M
3941	16722632	YSA*G	15	4	21.2% inhibition at 10^-3M
3965	16722632	YRA*G	16	4	15.6% inhibition at 10^-3M
3990	16722632	YA*GFM	17	5	22.8% inhibition at 10^-3M
4015	16722632	YA*GFM	18	5	9.6% inhibition at 10^-4M
4016	16722632	YA*GFM	18	5	29.9% inhibition at 10^-3M
4026	16722632	YGGFMA*	23	6	2.2% inhibition at 10^-6M
4027	16722632	YGGFMA*	23	6	7.1% inhibition at 10^-5M
4028	16722632	YGGFMA*	23	6	6.9% inhibition at 10^-4M
4029	16722632	YGGFMA*	23	6	25.9% inhibition at 10^-3M
4570	22023734	GRRKRKWLRRIGKGVKIIGGAALDHL	NRC-03	26	70% cytotoxic at 50 µM
4571	22023734	RWGKWFKKATHVGKHVGKAALTAYL	NRC-07	25	70% cytotoxic at 50 µM
4572	22023734	GWRTLLKKAEVKTVGKLALKHYL	NRC-13	23	0% cytotoxic at 50 µM
4573	22023734	GRRKRKWLRRIGKGVKIIGGAALDHL	NRC-03	26	60-70% cytotoxic at 50 µM
4574	22023734	RWGKWFKKATHVGKHVGKAALTAYL	NRC-07	25	60-70% cytotoxic at 50 µM
4575	22023734	GWRTLLKKAEVKTVGKLALKHYL	NRC-13	23	~5% cytotoxic at 50 µM
4619	20964334	KWKWKW	Dex-(KW)3	6	at 10 µM 35-40% viablity
5001	24587350	GIGKFLKKAKKFGKAFVKILKK	Pexiganan	22	LC₅₀= 8 at 100 µM
5002	24587350	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	LL 37	37	LC₅₀= 21 at 100 µM
5058	24830845	ETFSDWWKLLAE	mt_L22 W/P27A	12	IC₅₀=16.3 µM
5059	24830845	LTFSDWWKLLAE	mt_E17L/L22 W/P27A	12	IC₅₀=15.1 µM
5060	24830845	ESFSDWWKLLAE	mt_T18S/L22 W/P27A	12	IC₅₀=27 µM
5061	24830845	ETFADWWKLLAE	mt_S20A/L22 W/P27A	12	IC₅₀= 8.7 µM

CancerPPD :Database of Anticancer peptides and Proteins

Browse Result page of CancerPPD